Drugs / Puerarin

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 24 trials
Phase 2 NCT06968208 Aug 2025 → Jan 2029 expected metabolic disease, obesity and hypopigmentation Ruijin Hospital Not yet recruiting No outcome recorded
Phase 2 NCT03676296 Sep 2018 → Apr 2021 The University of Hong Kong Completed No outcome recorded
Phase 2 NCT03016793 Jan → Jun 2017 orofacial cleft Cairo University Unknown No outcome recorded
Phase 2 NCT02254655 Nov 2013 → Sep 2017 rheumatoid arthritis Chengdu PLA General Hospital Completed No outcome recorded
Phase not applicable1 trial
NCT02219191 Aug 2014 → Dec 2018 rheumatoid arthritis Chengdu PLA General Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00854724 Comparator Feb 2009 → Mar 2011 alcohol abuse Mclean Hospital Completed No outcome recorded
Phase not applicable1 trial
NCT02264301 Comparator Aug 2014 → Dec 2017 rheumatoid arthritis Chengdu PLA General Hospital Unknown No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as puerarin ClinicalTrials.gov intervention name — accepted as the source's own label NCT02219191
6

NCT03016793

NCT02254655

NCT03676296

NCT06968208

NCT00854724

NCT02264301

Known as Daidzein 8-c-glucoside ChEMBL registry synonym — accepted as the source's own label CHEMBL486386
Known as Kakonein ChEMBL registry synonym — accepted as the source's own label CHEMBL486386
Known as NPI 031G ChEMBL registry synonym — accepted as the source's own label CHEMBL486386
Known as NSC-380711 ChEMBL registry synonym — accepted as the source's own label CHEMBL486386
Known as Puerarin 80 mm ChEMBL registry synonym — accepted as the source's own label CHEMBL486386
Modality Small molecule CHEMBL486386
Route Oral “Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks.” NCT02219191